FogPharma Stock

fogpharma.comHealthcare / BioTech & PharmaFounded: 2016Funding to Date: $506.63MM

FogPharma is a clinical-stage biotechnology research company striving to develop HeliconTM peptides, an innovative approach aimed at overcoming current medication limitations and creating drug solutions for all human disease drivers. The Helicons are intended to act similarly to antibodies and be allocated across tissue as they interact with small molecules within the cells, whereas most modern tailored medications have difficulty reaching these target areas. FogPharma was founded in 2016 and is headquartered in Cambridge, Massachusetts.

Register To Buy and Sell Shares

For more details on financing and valuation for FogPharma, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access FogPharma’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like FogPharma.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

FogPharma investors also invested in these private companies

Farallon Capital Management
HBM Healthcare Investments
WuXi AppTec
6 Dimensions Capital
Milky Way Investments Group
Blue Pool Capital
Leerink Partners
Pivotal Life Sciences
Boyu Capital


Management Team

Mathai Mammen MD, Ph.D.
Chief Executive Officer & President
Rohin Mhatre Ph.D
Chief Technical Operations Officer
Gregory Miller MPH, MBA
Chief Business Officer
Keith Orford MD
Chief Medical Officer & Executive Vice President of Clinical and Translational Science
Kristen Stants MILR
Chief People Officer

Board Members

Jeffrey Leerink
Leerink Partners
Krishna Yeshwant MD
Alexis Borisy
Nextech Invest

Frequently Asked Questions About FogPharma’s Stock

Can you buy FogPharma’s stock?
FogPharma is not publicly traded on NYSE or NASDAQ in the U.S. To buy FogPharma’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell FogPharma’s stock?
Yes, you can sell stock of a private company like FogPharma. Forge can help you sell your FogPharma stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is FogPharma’s stock price?
FogPharma is a privately held company and therefore does not have a public stock price. However, you may access FogPharma’s private market stock price with Forge Data.
What is FogPharma’s stock ticker symbol?
FogPharma does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

FogPharma pulls in $145M to support cancer drug research
FogPharma elevated its financing with a series E funding round to continue its cancer pharmaceutical research expansion.
FogPharma’s $178M Funding Leads Way as 7 Biotechs Raise Cash for Cancer Drugs.
FogPharma is preclinical, but not for long. The biotech’s Series D financing round lays the groundwork to bring its lead program into the clinic in mid-2023, as well as support development of the rest of its pipeline of peptide drugs.
FogPharma Nets $178M Series D to Tackle Tough Targets
FogPharma has netted a $178 Million Series D financing to develop Helicon polypeptide therapeutics against hard targets.
Updated on: Apr 15, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.